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ABSTRACT 
The aim of study was to design development and optimize a controlled release system of Torsemide. to increase its bioavailability by increasing 
the residence time in the stomach without contact with the mucosa, and was achieved through the preparation of floating granules by melt 
granulation techniques. Torsemide; a loop diuretic used in the treatment of congestive heart failure and edema was chosen as the drug 
candidate to be formulated as gastro retentive multiparticulate system as it is a weakly basic drug with a short half-life of 2-3 hrs. Gelucire 
43/01 was selected as a lipid carrier in different ratio (1:0.5, 1:1, 1:1.5) along with drug. The formulation F1 to F6 were prepared and evaluated 
for dependent variable (in vitro floating ability) and formulations F4 to F6 were selected as preliminary optimized formulation. The preliminary 
optimized formulation F4 to F6 were evaluated for micromeritic properties, drug content and percentage yield, in-vitro drug release,  percentage 
in-vitro floating ability and formulation F4 was selected as optimized formulation that exhibited good floating ability and zero order drug 
release (85.95 %) at the end of 8 hours. Aging effect on storage was evaluated using In-vitro drug release. The In-vitro drug release study of the 
aged sample showed increase in release behaviour, it may be due to phase transformation of Gelucire. In conclusion, hydrophobic lipid, Gelucire 
43/01 can be considered as an effective carrier for design of a multi-unit floating drug delivery system of Torsemide. 
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Buccal route is measured as the most auspicious route of 
drug delivery. Conventional drug delivery system achieves 
as well as maintains the drug concentration within the 
therapeutically effective range needed for treatment, only 
when taken several times a day 1. This results in a significant 
fluctuation in drug levels. Recently, several technical 
advancements have led to the development of several novel 
drug delivery systems (NDDS) that could revolutionize 
method of medication and provide a number of therapeutic 
benefits 2. The most important objectives of these new drug 
delivery systems are: First, it would be single dose, which 
releases the active ingredient over an extended period of 
time. Second, it should deliver the active entity directly to 
the site of action, thus, minimizing or eliminating side 
effects. To overcome the limitations of conventional drug 
delivery system, floating tablets have been developed. Drugs 
that have narrow absorption window in the gastrointestinal 
tract (GIT) will have poor absorption. For these drugs, 
gastroretentive drug delivery systems offer the advantages 
in prolonging the gastric emptying time. To formulate a 
successful stomach specific or gastroretentive drug delivery 
system, several techniques are currently used such as 
hydrodynamically balanced systems (HBS) / floating drug 
delivery system 3, low density systems 4‐6, raft systems 
incorporating alginate gels 7‐9, bioadhesive or mucoadhesive 
systems 10, high density systems 11‐13, super‐porous 
hydrogels 14 and magnetic systems 15‐17. Swellable, floating 
and sustained release tablets are developed by using a 
combination of hydrophilic polymer (hydroxypropyl 
methylcellulose), swelling agents (crospovidone and 
croscarmelose) and effervescent substances (sodium 
bicarbonate and citric acid). Oral Controlled release drug 
delivery systems (OCRDDS) that can be retained in the 
stomach for a long time have many advantages over 
sustained release formulations. Controlled drug delivery 
system release the drug in a controlled and prolonged 
manner, so that the drug could be supplied continuously to 
its absorption site in the upper gastrointestinal tract. 
Development of controlled release oral drug delivery system 
(CRDDS) by overcoming physiological adversities like short 
gastric residence times and unpredictable gastric emptying 
times. One of the most feasible approaches for achieving a 
prolonged and predictable drug delivery in the GI tract is to 
control the gastric residence time (GRT), i.e. controlled 
release gastro retentive dosage form (CRGRDFS or GRDDS). 
18 Controlled release Gastro retentive drug delivery systems 
(GRDDS) are the systems which are retained in the stomach 
for a prolonged period of time and thereby improved the 
Singh et al                                                                                                            Journal of Drug Delivery & Therapeutics. 2019; 9(2-s):480-485 
ISSN: 2250-1177                                                                                  [481]                                                                                 CODEN (USA): JDDTAO 
bioavailability. GRDFs extend significantly the period of time 
over which the drugs may be released. They not only 
prolong dosing intervals, but also increase patient 
compliance beyond the level of existing controlled release 
dosage form 19. 
MATERIALS AND METHODS 
Materials and Equipments 
Torsemide, Gelucire 43/01 (Gattefosse St Priest, Cedex, 
France). Acetone (Sd fine-chemicals). Potassium chloride (Sd 
fine-chemicals). Hydrochloric acid,  Potassium dihydrogen 
phosphate, Sodium hydroxide pellets, Ethanol (Sd fine-
chemicals), Dissolution rate test apparatus(Electrolab Pvt. 
Ltd. Mumbai), pH /mill voltmeter(Century instrument Pvt. 
Ltd.), UV-VIS spectrophotometer(Shimadzu Corp. Japan), 
Standard test sieves(HICON, Grover Enterprises, Delhi), 
Digital oven(Science tech Pvt. Ltd. India), Digital Electronic 
Balance (Shinko Denshi corp. Japan), Digital M. P. 
apparatus(Jindal Scientific instruments, Ambala), Single Pan 
Electronic Balance(Contech instrument pvt. Ltd. Mumbai), 
Magnetic Stirrer with Hot Plate (B.D. Scientific Industries, 
Delhi).                       
Preparation of granules of torsemide 
Melt granulation technique (MG) 
Lipid was melted at 50 - 60 oC, and the drug was added, 
mixed well, and cooled to room temperature. The mass was 
passed through a 710-µm (22 mesh) sieve to obtain uniform- 
sized granules. 20, 21 
The formulation codes of the granules prepared are listed in 
Table 1. 
 
Table 1: Formulation codes of Torsemide granules 
Method of 
preparation 






F1 1 0.5 - 
F2 1 1 - 
F3 1 1.5 - 
F4 1 - 0.5 
F5 1 - 1 
F6 1 - 1.5 
 
Selection of preliminary optimized formulations 
Formulations F1 to F6 were prepared and evaluated for 
dependent variable like percentage floating ability. On the 
basis of dependent variable the optimized formulations were 
selected having good floating ability. 20 
Determination of floating behavior 
Twenty unit granules were placed in 900 ml of distilled 
water and pH 6.8 phosphate buffers in a vessel maintained at 
37oC ± 0.5oC and stirred at 100 rpm in USP 24 type II 
dissolution test apparatus. The percentage of floating 
granules up to 8 hours was determined and the floating 
times were measured by visual observation.20 
Evaluation of preliminary optimized formulations 20 
Micromeritic properties 
Determination of bulk and tapped density 
2g of different optimized formulations was subjected into 10 
ml graduated measuring cylinder separately and the volume 
was noted down. The graduated cylinder was tapped 50 
times using bulk density apparatus. The bulk density and 
tapped density was determined using following formula 
(Aulton et al 2002). 
Bulk density = 
                            
                 
 
 
Tapped density = 
                            
                          
 
 
Determination of granule density 
Granule density of different formulation was determined by 
liquid displacement method (Martin et al 1999) by 
suspending the granules in a solvent in which the granules 
were insoluble. 
Determination of hausner’s ratio 
The density determinations were used to determine the 
Hausner’s ratio and could be determined using following 
formula.22 
Hausner’s ratio =
                
               
 
Determination of Carr’s compressibility index 
The density determinations were used to determine the 
carr’s compressibility index and could be determined by 
following formula.22 
Carr’s compressibility index =
               –              
              
      
Determination of angle of repose (θ) 
The angle of repose of different formulation was determined 
by fixed funnel method and could be determined by using 
following formula. 22 
            Angle of Repose (θ) = tan-1(h / r)                                        
Where, 
h and r are height of pile and radius of the base of the pile 
respectively. 
Determination of drug content and percentage yield 
Ten milligrams of floating granules were added to 10 ml of 
pH 6.8 phosphate buffer, heated to 60 oC to 70 oC, and 
allowed to cool to room temperature. The lipid was solidified 
and the drug solution was filtered through whatman no. 1 
paper (whattman plc, middlesex, uk). The sample was 
analyzed for drug content by UV spectrophotometry at 290 
nm after suitable dilutions. Determinations were performed 
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Determination of in-vitro floating ability 
Twenty unit granules were placed in 900 ml of pH 6.8 
phosphate buffers in a vessel maintained at 37oC ± 0.5oC and 
stirred at 100 rpm in USP 24 type II dissolution test 
apparatus. The percentage of floating granules up to 8 hours 
was determined and the floating times were measured by 
visual observation.20 
% of floating ability = Nf / (Nf  + N s) x 100 
Where, Nf and Ns are numbers of the floating and settled 
granules respectively. 
In -vitro drug release studies 
Dissolution of Torsemide from different formulations were 
studied in 900 ml of pH 6.8 phosphate buffer using a USP 
apparatus 2 (paddle type) dissolution rate test apparatus. 
Samples equivalent to 50 mg of Torsemide was used in each 
test at 100 rpm and temperature 37 ± 0.5 °C. Samples (5 ml) 
were withdrawn at predetermined time intervals till 8 hours, 
immediately replaced with fresh dissolution medium and 
analyzed for Torsemide content at 290 nm after suitable 
dilution. Percent of Torsemide dissolved at various time 
intervals was calculated from the regression equation 
generated from the suitably constructed calibration curve. 
The release studies were conducted in triplicates. 20 
 
Model Fitting 
Values obtained from drug release from different 
formulations in pH 6.8 phosphate buffer were subjected for 
model fitting parameters (zero order, first order, Higuchi, 
Hixson- Crowell and Peppas). 
Selection of Optimized Formulation 
The optimized formulation was selected on the basis of 
model fitting parameters shown by the formulation. 
Effect of Aging 
The optimized was stored upto one month at room 
temperature (25°C) in order to detect physical changes. 
(structural or polymorphic) on aging associated with 
glyceride bases. The effect of aging on optimized formulation 
was studied by in- vitro drug release.20 
RESULTS AND DISCUSSION 
Selection of Preliminary Optimized Formulations 
 Formulations F1 to F6 were prepared and evaluated for 
dependant variable (Table 2) like percentage floating ability. 
On the basis of percentage floating ability formulations F4, F5 
and F6 were selected as optimized formulations as it 
exhibited good floating ability. Formulations F1, F2 and F3 
were rejected based on low value of percentage floating 
ability.  
 
Table 2: Observation table of invitro floating ability in distilled water and pH 6.8 phosphate buffer 
 
Formulation Code 
In-vitro floating ability 
Distilled Water pH 6.8 phosphate buffer 
F1 Sink (within 1 hour) Sink (within 1 hour) 
F2 Sink (within 1 hour) Sink (within 1 hour) 
F3 Sink (within 1 hour) Sink (within 1 hour) 
F4 Float (8 hours) Float (8 hours) 
F5 Float (8 hours) Float (8 hours) 
F6 Float (8 hours) Float (8 hours) 
 
  
Evaluation of Preliminary Optimized Formulations 
 All the preliminary optimized formulations (F4-F6) were 
evaluated for variable parameters and the optimized 
formulation was selected. 
Micromeritic properties 
Determination of bulk density and tapped density 
The bulk density and tapped density was determined using 
bulk density apparatus (Aulton et al 2002) and represented 
in Table 3. The bulk density and tapped density of 
preliminary optimized formulations (F4-F6) were found to be 
in the range of 0.276- 0.292g/cm3 and 0.323- 0.334g/cm3. 
Determination of granule density 
The granule density, measured by liquid displacement 
method by suspending the granules in a solvent in which the 
granules were insoluble like liquid paraffin , ranged from 
0.695 - 0.781  g / cm 3 , which is less than 1.004 g / cm 3 
(Vyas and Khar 2002) , the specific gravity of the gastric 
fluid, substantiating the buoyant properties of the granules. 
 





















F4 0.276±0.0015 0.331±0.0030 0.753±0.0021 1.199±0.0014 16.61±0.023 17.210±0.015 
F5 0.284±0.0021 0.323±0.0026 0.781±0.014 1.137±0.0019 12.07±0.030 15.630±0.029 
F6 0.292±0.0020 0.334±0.0028 0.695±0.010 1.143±0.0018 11.59±0.19 16.260±0.040 
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The Hausner’s ratio of different formulations were 
determined and found to be in the range of 1.137 – 1.199 and 
indicated good flow property. 
Determination of Carr’s compressibility index 
The Carr’s compressibility index of different formulations 
were determined and found to be in the range of 11.59- 
16.61% which indicated fair to passable flow property. 
Determination of angle of repose (θ)  
The angle of repose of different formulations were 
determined and found to be in the range of 15.63- 17.210 
indicated excellent flow property.  
Determination of drug content and percentage yield 
The percentage yield and drug content of different 
formulations were determined and represented in Table 
4.The percentage yield and drug content was found in the 
range of 89.36 - 92.54 and 97.28 - 98.17%. Low values of 
standard deviation indicated the uniformity in drug content. 
Table 4; Observation table of percentage yield and 





Drug content(%) ± 
S.D. 
F4 92.54 97.28± 0.545 
F5 90.36 98.17± 0.676 
F6 89.36 97.41± 0.496 
 
Determination of in-vitro floating ability  
The percentage in-vitro floating ability of different 
formulations were determined and represented in Table 5. 
Formulations F4 – F6 exhibited 90 to 100 % floating ability at 
the end of 8 hours in pH 6.8 phosphate buffer. This is due to 
the lower bulk density of the formulations and hydrophobic 
nature of Gelucire 43/01 used in granules. 
Table 5: Observation table of percentage in-vitro floating 
ability in pH 6.8 phosphate buffer. 
Formulation 
code 
Percentage in-vitro floating 
ability 





In-vitro drug release studies 
The in-vitro drug release profiles of the granules prepared by 
melt granulation (F4-F6) were compared with that of pure 
drug. In the fed state gastric pH ranges from more than pH 
2.0 –pH 6.5 (Arora et al 2005), therefore pH 6.8 was selected 
as fed state gastric pH.In fed state, at pH 6.8, the pure drug 
showed 99.79 % while formulation F4, F5 and F6 showed 
85.95 %, 79.95 % and 77.83  %  drug release after 8 hours 
respectively. 
As the Gelucire 43/01 ratio was increased in the 
formulations F4 to F6 prepared by melt granulation 
technique, the release rate was lowered due to hydrophobic 
nature of Gelucire 43/01. The analysis of data was done 
using PCP Disso v2.08 software.  
Release Kinetics of Preliminary Optimized Formulations 
Regression coefficient, n and k values were obtained for zero 
order, first order, Higuchi, Hixson Crowell and peppas from 
the values obtained from % drug release. The in-vitro drug 
release profiles were clarified by the data obtained from 
model fitting. Model dependent parameters showed zero 
order models as the best fit model. It was concluded that 
formulation F4 prepared by melt granulation with Drug: 
Gelucire 43/01 ratio 1:0.5 followed zero order release 
kinetics as the best fit model. 
 
 
Figure 1: Comparative % drug release profile in pH 6.8 phosphate buffer 
 
Selection of Optimized Formulation 
The formulations F4 to F6 were evaluated for different 
evaluation parameters like micromeritic properties, 
percentage in-vitro floating ability, percentage yield and drug 
content and in vitro drug release. Model dependent 
parameters were calculated. It was concluded that 
formulation F4 prepared by melt granulation with Drug: 
Gelucire 43/01 ratio 1:0.5 followed zero order release 
kinetics as the best fit model.                                      
Effect of Aging 
In-vitro drug release 
In-vitro drug release profiles of granules on aging (after 10 
and 30 days) were shown in Figure 2. Drug release increased 
on aging, which might be attributed to the phase 
transformation. The floating ability of the granules was not 
affected by aging. The zero order kinetics shown by aged 
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Figure 2: Release profile of Torsemide from formulation F4 showing effect of aging 
 
CONCLUSION 
The present study was aimed to prepare floating granular 
delivery system with an objective to control the release rate 
of Torsemide. The performance of the formulations was 
evaluated and the floating ability of the granules and the 
release rate of the drug (Torsemide.) from the granules can 
be controlled by changing the composition ratio of Gelucire 
43/01. Formulation F4 (Drug: Gelucire 43/01 ratio 1:0.5) 
exhibited good buoyancy and drug release (85.95%) with 
zero order release pattern selected as optimized formulation. 
The study demonstrated that hydrophobic lipid Gelucire 
43/01, can be as an effective carrier for the design of a multi 
unit floating drug delivery system of Torsemide. Torsemide, 
is a loop diuretics that prevent that the body from absorbing 
too much salt, allowing the salt to instead be passed in urine. 
It is used in treatment of congestive heart failure and odema. 
Torsemide belongs to the biopharmaceutical classification 
system class IV i.e. Torsemide has low permeability and low 
solubility. It oral bioavailability is 40-60%.The poor aqueous 
solubility and poor dissolution rate of the drug may have 
negative impact on it bioavailability. Estimation of 
Torsemide was carried spectrophotometric ally by UV 
method at290nm.the pre -formulation study involving FTIR 
show that no interaction between drug and polymer. The 
stability study indicates that there is no degradation of drug 
in the formulation. Hence the Torsemide was selected for the 
formulation .As it was important the overall bioavailability of 
Torsemide. it absorption throughout the intestine was also 
focused. The sustain release floating granules of the 
Torsemide is made by the melt granulation technique. Such 
formulation is achieve sustained released of drug in 
intestine, so that sustain absorption can be achieve. The drug 
released profile of the developed formulation in compression 
with the marketed formulation indicated a definite 
improvement in the drug release pattern throughout gastro 
intestine pH. The main aim of the design and optimize 
controlled release system of Torsemide is to increase the                                                                                                                                                                          
bioavailability by increasing residence time in the stomach 
without contact with mucosa. The Torsemide is formulated 
as a gastro retentive multiparticulate system as it is a weekly 
basic drug with sort half-life of 2-3 hrs. The gelucire 43/01 
and50/13was selected as lipid carrier in different ratio 
(1:05, 1:1, and 1:5) along with drug. There were six 
formulation are developed (F1, F2, F3, F4, F5, F6) in which 
F1-F6 are dependent variables while F4-F6 where selected 
as preliminary optimized formulation. Thus by adopting the 
principle of solubility enhancement and sustain release 
floating granules was obtained in to improve the 
bioavailability of drug. Gastro retentive systems can remain 
in the gastric region for several hours and hence significantly 
prolong the gastric residence time of drug .Prolong gastric 
retention improve bioavailability ,reduces drug waste, and 
improve solubility for drug  that are less soluble in a high PH 
environment. It has application also for local drug delivery to 
the stomach and proximal small intestine. Gastro retention 
helps to provide better availability of new products with new 
therapeutic possibilities substantial benefits for patients. The 
multi-unit dosage such as floating granules may be more 
suitable because of slow release of drug at desired rate 
system. The expulsion of the floating system from stomach 
after complete release of drug. The reduction of dosing 
frequency may also found. It is increase in gastric residence 
time. Instead of it have low dose and no first pass hepatic 
metabolism. The Torsemide drug has soluble in acetone, 
ether and sparingly soluble in ethyl alcohol. It melting point 
has 210c.There excretion been found renal 66%, bilary 33%.  
The major site of action is the thick ascending limb loop of 
Henley where Torsemide inhibits Na+-K+-2Cl- co transport. 
A minor component of action on proximal tubule has been 
indicated. It secreted in proximal tubule by organic anion 
transport and reaches ascending limb loop of Henley where 
it on act luminal side of the membrane. Metabolishes the 
corticomedullary osmotic gradient and block positive as well 
as negative free water clearance+ is increased mainly due to 
high Na+ load   reaching distal tubule. Torsemide has weak 
carbonic anhydrase inhibitory on acid base balance of the 
body and it causes the little distortion of the same; mild 
alkalosis occurs at high doses. It may inter act with the 
Indomethacin, Lithium, aspirin and other salicylate. It has lot 
of side effect like Hypokalemia, Acute saline depletion, 
hearing loss etc.  
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